Literature DB >> 10602408

Human immunodeficiency virus type 1 TAT protein induces adhesion molecule expression in astrocytes.

S E Woodman1, E N Benveniste, A Nath, J W Berman.   

Abstract

AIDS encephalitis is a frequent consequence of CNS HIV infection, especially in children. One of its many characteristics is a leukocyte infiltrate that is believed to contribute to the production of cytokines, chemokines and neurotoxic factors resulting in CNS damage. Entry of such leukocytes into the CNS is mediated in part by the expression of adhesion molecules by blood - brain barrier (BBB) endothelial cells. Expression of these proteins by astrocytes, the other main component of the BBB, also serves to target leukocytes to the CNS parenchyma. We now demonstrate that HIV-1-derived Tat, a soluble protein secreted by infected cells, induced astrocyte VCAM-1 and ICAM-1 expression in a dose- and time-dependent manner. The functional role of Tat in monocyte binding in vitro was also demonstrated. These data suggest that the presence of extracellular Tat may be a significant factor in the trafficking of HIV-infected and inflammatory cells into the CNS via its effect on adhesion molecule expression by astrocytes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10602408     DOI: 10.3109/13550289909021296

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  18 in total

Review 1.  Epidemiological evidence and molecular basis of interactions between HIV and JC virus.

Authors:  J R Berger; A Chauhan; D Galey; A Nath
Journal:  J Neurovirol       Date:  2001-08       Impact factor: 2.643

2.  HIV-1 Tat-mediated neurotoxicity in retinal cells.

Authors:  Nivedita Chatterjee; Shannon Callen; Gail M Seigel; Shilpa J Buch
Journal:  J Neuroimmune Pharmacol       Date:  2011-01-28       Impact factor: 4.147

Review 3.  Chemokines and glial cells: a complex network in the central nervous system.

Authors:  Elena Ambrosini; Francesca Aloisi
Journal:  Neurochem Res       Date:  2004-05       Impact factor: 3.996

Review 4.  Astrocyte, the star avatar: redefined.

Authors:  Pankaj Seth; Nitin Koul
Journal:  J Biosci       Date:  2008-09       Impact factor: 1.826

Review 5.  Blood-brain barrier integrity and glial support: mechanisms that can be targeted for novel therapeutic approaches in stroke.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

6.  Mechanisms of HIV-tat-induced phosphorylation of N-methyl-D-aspartate receptor subunit 2A in human primary neurons: implications for neuroAIDS pathogenesis.

Authors:  Jessie E King; Eliseo A Eugenin; Joy E Hazleton; Susan Morgello; Joan W Berman
Journal:  Am J Pathol       Date:  2010-05-06       Impact factor: 4.307

7.  Biomarkers of chemotaxis and inflammation in cerebrospinal fluid and serum in individuals with HIV-1 subtype C versus B.

Authors:  Sergio M de Almeida; Indianara Rotta; Yanxin Jiang; Xiao Li; Sonia M Raboni; Clea E Ribeiro; Davey Smith; Michael Potter; Florin Vaida; Scott Letendre; Ronald J Ellis
Journal:  J Neurovirol       Date:  2016-07-11       Impact factor: 2.643

Review 8.  Neuroprotective strategies for HIV-1 associated dementia.

Authors:  Huanyu Dou; Jeffrey D Kingsley; R Lee Mosley; Harris A Gelbard; Howard E Gendelman
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

9.  Inflammatory changes and breakdown of microvascular integrity in early human immunodeficiency virus dementia.

Authors:  Malcolm J Avison; Avindra Nath; Robin Greene-Avison; Frederick A Schmitt; Rodney A Bales; As'ad Ethisham; Richard N Greenberg; Joseph R Berger
Journal:  J Neurovirol       Date:  2004-08       Impact factor: 2.643

Review 10.  Neuroimmunity and the blood-brain barrier: molecular regulation of leukocyte transmigration and viral entry into the nervous system with a focus on neuroAIDS.

Authors:  Clarisa M Buckner; Aimée J Luers; Tina M Calderon; Eliseo A Eugenin; Joan W Berman
Journal:  J Neuroimmune Pharmacol       Date:  2006-04-13       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.